Syros Pharmaceuticals Inc. (SYRS)
Market Closed
19 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary 
LSE $
0. 00
-0
-75%
$
10.73K Market Cap
4.89 P/E Ratio
- Div Yield
6,918 Volume
-4.76 Eps
$ 0
Previous Close Analysts:
Want to track SYRS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing.
Seekingalpha | 1 year ago
